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MinireviewSleeping with the Enemy—
Endogenous Superantigens in Humans
amplification of MMTV RNA was on the order of 105–106.
This amplification was in part due to more efficient viral
production and in part due to the proliferation of infected
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1300 York Avenue B cells (Held et al., 1994). There was no evidence for a
SAg-independent pathway of MMTV transmission andNew York, New York 10021
only MMTV with functional sag genes could be transmit-
ted through milk (Golovkina et al., 1995). Thus, the life
cycle of exogenous MMTV was dependent on SAg ex-We usually think of superantigens (SAg) as dangerous
pression. In general, optimal replication of retrovirusestoxins that may cause toxic shock syndrome and death
requires actively dividing host cells. MMTV-encoded(Marrack and Kappler, 1990). Now, based on two pa-
SAg appeared to stimulate the immune system (T andpers in this issue of Immunity, it seems that we all
B cells) to provide such conditions.have SAg genes within us, lying dormant and waiting
On the other hand, it was suggested that sag encodedto be activated under special circumstances (Sutkow-
by an endogenous provirus conferred a selective advan-ski et al., 2001; Stauffer et al., 2001).
tage on the mouse that carried it. The responding V
subsets were deleted or became tolerant to the self-
SAg are a group of microbial proteins that target the (super)antigen. As a result, these mice could avoid infec-
immune system, causing massive polyclonal T cell acti- tion with exogenous MMTV that encode sag with the
vation and cytokine release, often followed by T cell same V specificity. If this was a successful evolutionary
apoptosis or anergy. SAg differ from conventional pep- strategy to prevent infection with exogenous retrovi-
tide antigens. They are not processed into small pep- ruses in mice, one might expect that other species would
tides by antigen-presenting cells, and they bind to MHC have integrated similar endogenous sag genes. Until
class II outside of the peptide groove. They interact with now, there was little evidence for this.
the TCR in an unusual way, via amino acid residues
encoded by the V genes of the TCR rather than with Endogenous Superantigens in Humans
the highly variable, non-germline-encoded residues of A provocative paper (Conrad et al., 1997) provided the
the TCR  and  chain CDR3 regions. Thus, large per- first evidence of possible endogenous human SAg. Con-
centages of T cells expressing the same V genes are rad and colleagues were studying type I diabetes and
stimulated. found high percentages of V7 T cells infiltrating the
pancreatic islets in several patients. This was attributed
Mouse Mammary Tumor Virus Superantigens to endogenous SAg encoded by the env gene of a human
Endogenous sag were first discovered by Festenstein in endogenous retrovirus (HERV), initially named IDDMK1,222
1973 and referred to as “minor lymphocyte-stimulating” and later found to be identical to HERV-K18. This SAg
(Mls) antigens. Mls antigens expressed on B lympho- was specific for V7 T cells. In addition, viral RNA was
cytes were able to induce massive T cell proliferation found in plasma samples from newly diagnosed IDDM
in mixed lymphocyte reactions between MHC-identical patients. However, other groups were unable to repro-
strains of mice. Much later, it was shown that Mls genes duce these findings (Murphy et al., 1998; Lower et al.,
were encoded by genomic copies of endogenous sag 1998; Lan et al., 1998; Lapatschek et al., 2001).
genes that had been pirated from the exogenous ge- An important lead was provided when HERV-K18 was
nomes of mouse mammary tumor viruses (MMTV) (re- found to be located within the first intron of CD48 on
viewed in Acha-Orbea and MacDonald, 1995). The sag chromosome 1 (Hasuike et al., 1999). The group of Huber
gene, it turned out, partly overlapped with the 3LTR of had been studying a SAg-like activity associated with
MMTV in a location similar to the nef gene of HIV. Each EBV infection (Sutkowski et al., 1996), and CD48 expres-
MMTV-encoded SAg varies in the C-terminal region, sion was known to be induced in EBV-infected B cells,
conferring the TCR-V specificity of this type II protein. with an identified upstream EBV-inducible enhancer.
The biological function of sag genes was revealed in In this issue of Immunity, this group shows that the
an elegant experiment (Golovkina et al., 1992). C3H mice previously described EBV-related SAg activity is in fact
transmit an exogenous MMTV vertically from mothers encoded by alleles of the HERV-K18 env gene (Sutkow-
to pups. The sag gene from this virus was used to create ski et al., 2001). The more common K18.1 and K18.2
transgenic mice that overexpressed the SAg during thy- alleles were both found to encode sag genes specific for
mic maturation and, as a result, deleted the targeted TCR V13 and V9. EBV infection led to transcriptional
V14-bearing T cells. These mice were resistant to infec- activation of HERV-K18 env and the EBV-associated
tion with exogenous MMTV. These studies were ex- SAg activity was blocked with an antiserum to HERV-
tended (Held et al., 1993) with the discovery that infec- K18 env. In the other paper from Conrad’s group (Stauf-
tion by exogenous MMTV from maternal milk was fer et al., 2001 [this issue]), three alleles of HERV-K18
critically dependent on T cell help provided by the SAg- env were identified and were discriminated from other
targeted V subset. Due to the presence of SAg, initial KERV-K provirus genes based on their insertion site
within the CD48 intron, an achievement that was essen-
tial for this work. All three had SAg activity and stimu-1 Correspondence: dposnett@med.cornell.edu
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lated primarily V7 (and possibly V13.1) T cells. K18.1 with MMTV or JSRV (Jaagsiekte sheep retrovirus). HERV
are thus thought to represent evolutionary fossils fromwas identical to IDDMK1,222 and contained a stop codon
at residue 153, while K18.2 and K18.3 encoded the full- earlier retroviruses. Some of these retroviruses may
have plagued apes, as the HERV-K family dates backlength protein. Thus, the SAg activity seems to be con-
tained within the N-terminal150 amino acids. Expres- in evolution to the divergence of Old and New World
monkeys.sion of the HERV-K18 alleles was strongly induced by
IFN treatment of PBL. V7-specific SAg activity was HERV env genes seem to be conserved, suggesting
an important biologic function. Beneficial effects of en-inhibited with specific antisera to env peptides. Induc-
tion of HERV-K18 RNA by IFN occurred in CD2– cells dogenous retroviral env expression have been de-
scribed (Coffin, 1995). Some endogenous env confer(which include B cells) but not in CD2 cells.
The two papers together suggest that EBV, and per- resistance in mice to MLV, and in chickens to ALV, which
are viruses that use the same receptors as the endoge-haps other viruses, can induce endogenous sag genes
encoded by HERV and that type I interferons may be nous env-encoded protein. This resonates with the role
of endogenous MMTV described above. Other possiblepartly responsible for sag gene activation. However,
there are still a number of loose ends. Differences con- beneficial effects include mutagenesis due to retroviral
insertion. This can functionally delete a gene, but thecerning the V specificity observed in the two papers
need to be resolved. Even though both groups used the retroviral LTR can also provide enhancer elements lead-
ing to gene activation, as in the case of the duplicatedsame A20 transfectants, the SAg was specific for V13
and V9 in one study (Sutkowski et al., 2001) and V7 mouse C4 complement gene, or the salivary gland-spe-
cific expression of a duplicated human -amylase gene.(and perhaps V13) in the other study (Stauffer et al.,
2001). Differences in the methods used might be rele- Finally, HERV-W env genes have been proposed to play
a role in placental development by inducing trophoblastvant. For example, Sutkowski et al. treated their EBV
lymphoblastoid cell lines and their transfected cell lines fusion to generate the syncytiotrophoblast layer (Mi et
al., 2001).with PMA. Stauffer et al. used IFN to induce PBL-
derived APCs, and their A20 transfectants did not re-
quire pretreatment. There are seven BV13, three BV7, Conclusions and Significance
and one functional BV9 gene. Some are known to have Are the sag of HERV the same as those of MMTV? How
allelic variants. These various V family members and do SAg fit into the HERV story, and are all HERV env
even individual TCR V alleles, which differ at crucial genes endowed with SAg activity? Although these ques-
amino acid residues (Liao et al., 1996), may interact tions remain unanswered at present, we notice some
differently with SAg. Which of these gene products react differences between humans and mice. In mice, endoge-
with the HERV-K18 SAg has not yet been worked out. nous SAg cause large deletions of entire V families in
Finally, the polyclonal background T cell activation ob- certain strains, which are easily detectable at birth. In
served after 48 hr with the B95-8 LCL, which was com- striking contrast, the human V repertoire is quite uni-
pletely blocked by anti-env serum (Sutkowski et al., form at birth in the thymus, blood, and spleen (Doherty
2001), may have confounded analyses of V specificity et al., 1991; Garderet et al., 1998; Schelonka et al., 1998).
in some experiments. There are a few examples of variable V expression,
such as V3, V7.2, V13.2, V12.4, V20, V6.1, and
V6.7. In each case, genomic differences (genomic dele-Human Endogenous Retroviruses
All humans carry numerous copies of HERV in their ge- tion, null alleles, or other allelic mutations) in the TCR
genes themselves are the cause. One possible conclu-nome (reviewed in Lower et al., 1996). As opposed to
other retro-elements, HERV contain env genes. They are sion is that endogenous SAg are not expressed in human
ontogeny, unlike in mice. Consistent with this conclu-sometimes complete proviruses but they are usually
replication defective. There are at least nine families sion, self-tolerance to some HERV-K env products is
apparently incomplete. Normal sera contain low levelswith names like HERV-H, HERV-R, HERV-K, HERV-E,
HERV-I, etc., (where the letters denote the specific tRNA of specific autoantibodies to HERV-K10 Env synthetic
peptides. Higher levels are found after pregnancies andprimer binding site). HERV-R contains a single gene
(ERV-3), but other families are represented by 10-1000 in patients with leukemias and testicular carcinomas
(Lower et al., 1996) It is not known whether this alsogenomic copies. HERV-K, the family of K18, contains
10–50 genomic copies and has significant homology to applies to HERV-K18.
Even if HERV-encoded SAg lack biologically signifi-MMTV. It is a widely studied HERV family because the
provirus is complete and potentially capable of produc- cant roles in human fetal development, it is conceivable
that they contribute to disease pathogenesis in severaling viral particles, especially in situations favoring viral
complementation, as in retroviral infection or gene ther- different ways. Sutkowski et al. hypothesize that long-
term persistent EBV infection in B cells requires T cellapy. Some HERV-K genes are highly expressed in terato-
carcinomas and testicular tumors but also at lower levels help provided by SAg-stimulated T cells. Moreover, they
argue that certain human B cell lymphomas require Tin placenta and other tissues. HERV-K18 has a unique
expression pattern restricted to primary PBL, as deter- cell help during oncogenesis. An example of this sce-
nario was provided by elegant studies of B cell lympho-mined by a nested RT-PCR assay (Sugimoto et al., 2001).
In some studies, env-encoded peptides have been de- mas in SJL mice (Tsiagbe et al., 1993). These tumors
express an endogenous MMTV SAg, which elicits T celltected.
In spite of all these genomic copies of HERV genes, help from V16 CD4 T cells, required for tumor cell
growth. Another mechanism by which endogenous SAgthere are no known exogenous equivalents of HERV, as
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can promote tumor growth was discovered in experi- titis C, and metastatic melanoma. IFN may also be
ments with tumors induced by polyoma virus. Here the beneficial in autoimmune diseases like multiple sclero-
endogenous Mtv-7 SAg results in deletion of V6 T cells sis, but treatment with type I interferon may sometimes
that are critical in effective antitumor immunity, resulting induce autoimmune disorders, especially autoimmune
in an inherited susceptibility to these virus-induced thyroid disease (Belardelli and Gresser, 1996). Whether
tumors induction of endogenous sag genes, as suggested by
SAg can either transiently activate T cell subsets or Stauffer et al. (2001), plays a role in any of these effects
lead to their functional demise. The targeted T cell sub- is not yet known.
set may contain helpful T cells (e.g., those that lead to EBV may not be the only herpesvirus that can trans-
tumor rejection) or it may include potentially harmful T activate endogenous SAg in humans. Indeed, the origi-
cells (e.g., those that help the B cell lymphomas in SJL nal paper on the topic of herpesvirus SAg described a
mice). Therefore it is impossible to predict what clinical V12-specific SAg activity associated with CMV (Do-
effects SAg may have. However, it is possible to imagine brescu et al., 1995b). In part, those studies employed
how SAg may tip the balance one way or another, and U937 cells exposed to CMV. U937 cells express ERV-3
this applies not only to tumor immunology but also to of the single copy HERV-R family (Larsson et al., 1996).
infectious diseases and to autoimmunity. Obviously, de- It is currently not known whether this HERV env gene
letion of a critically necessary TCR specificity could is transactivated by CMV or other stimuli. It is also not
compromise an immune response to an infectious or- known whether this env gene encodes a protein with
ganism. But deletion of a regulatory T cell that down- SAg-like biological activity. One percent of normal Cau-
modulates the response may have the contrary effect. casians lack intact ERV-3 env due to homozygosity of
Stimulation of large numbers of T cells as in a SAg an allelic mutation, which results in a premature stop
response may result in high levels of cytokines. Some codon (de Parseval and Heidmann, 1998). However,
microbes use cytokines for their own needs, rather like even the shortened version of ERV-3 can encode an25
the tumors in SJL mice. However, S. aureus and S. kDa peptide (de Parseval and Heidmann, 1998). As with
pyogenes, the major source of exogenous SAg in hu- the short allele of HERV-K18 (K18.1) (Stauffer et al.,
mans, are not known to require cytokines for their 2001), a hypothetical superantigen function could be
growth. Indeed, it is a puzzle why these bacteria produce preserved.
SAg at all. It is also conceivable that viruses, such as In vivo, the picture may be even more complex. Fol-
HIV, which replicate most efficiently in activated lympho- lowing reports of SAg-like activity associated with EBV,
cytes, take advantage of large numbers of SAg-acti- CMV, and HIV infection, multiple efforts to isolate the
vated T cells (Dobrescu et al., 1995a) and that concurrent putative sag from these viruses were unsuccessful. With
chronic infection with EBV, CMV, or KSHV aggravates the discovery of endogenous sag genes, the old obser-
HIV by this mechanism. vations may need to be reexamined. For instance, it is
Because of reports of increased V7 cells in the pan- possible that the observed SAg-like activities might have
creas, spleen, and blood at the onset of IDDM, a patho- been due to the cumulative effects of multiple viruses
genic role for the HERV-K18 has been suggested (Stauf- (usually present together in vivo) through transactivation
fer et al., 2001). The idea that SAg can break tolerance of endogenous sag genes.
and contribute to autoimmunity is not new (Friedman et In sum, the potential significance of endogenous SAg
al., 1991; Schiffenbauer et al., 1998). As mentioned is considerable. For instance, can endogenous SAg
above, there is inherent incongruity in the responses to stimulate CD4 T cells in AIDS patients resulting in in-
SAg: exogenous bacterial SAg can aggravate experi- creased HIV replication? Can they stimulate select V
mental autoimmune encephalomyelitis (EAE) when subsets leading to autoimmunity, like IDDM, as sug-
given after myelin basic protein (MBP) or inhibit EAE gested by Conrad and colleagues? Can they delete or
when injected prior to MBP. Different SAg (SEA, SEB)
anergize critical T cell subsets that would otherwise
may have opposing effects, indicating that their specific-
protect the host from diseases?
ity is important and not just the high levels of cytokines
One point to remember is that we are constantly ex-that they provoke. However, the exact mechanisms in-
posed to SAg . Most adults have had contact with nu-volved still need to be elucidated. This is important be-
merous SAg of S. aureus and S. pyogenes. S. aureuscause studies with NOD mice have shown that exoge-
commonly colonizes the nose of normal persons. As anous SAg (SEA, SEB, and SEC2) administered at 4 or
consequence, we all have serum antibodies to bacterial10 weeks of age either block or ameliorate IDDM. It
SAg and these antibodies protect us from toxic shockwas further shown that SAg-activated CD4 suppressor
syndrome. So, how can endogenous SAg make a differ-T cells could inhibit disease after adoptive transfer (Ka-
ence? Some obvious differences are that bacterial SAgwamura et al., 1993). At first glance this seems to contra-
exposure is likely repetitive, occurs at low concentra-dict the proposed role for the HERV-K18 SAg in human
tions, and at mucosal and cutaneous surfaces. In con-IDDM. However, in addition to the varied specificities
trast, HERV-K SAg expression is apparently inducedof individual SAg, many other factors may play important
in professional antigen-presenting cells (B cells), androles, including dose, timing, and duration of SAg expo-
possibly in virus-infected cells. The exact conditionssure, tissue location of SAg production, and type of APC
and mechanisms that are operative in vivo for HERV-Kinvolved.
SAg production are not yet fully defined. Perhaps moreIt is well recognized that type I interferons (IFN or
is involved than just EBV and a little IFN. Future re-IFN) may influence T cell immunity. This can be benefi-
search will hopefully reveal the secrets of how we man-cial. For example, type I interferons are used clinically
for hairy cell leukemia, Kaposi’s sarcoma, chronic hepa- age to sleep with the enemy without getting hurt.
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